Michael Hofman, Nuclear Medicine Physician at Peter MacCallum Cancer Centre, shared a post on X about a recent paper by Daniel Gillett et al. published in Journal of Nuclear Medicine:

“18F-CETO for primary aldosteronism: a promising adrenal gland PET/C T – can distinguish aldosterone-producing adenomas from normal adrenal tissue, thereby improving the evaluation and management of primary aldosteronism.

Very nice work from Daniel Gillett.”

“A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism”

Authors: Daniel Gillett, Russell Senanayake, James MacFarlane, Franklin Aigbirhio, Mark Gurnell et al.

Michael Hofman: 18F-CETO for primary aldosteronism

More posts featuring Michael Hofman.